Development of subcutaneous panniculitis-like T-cell lymphoma after immune checkpoint inhibitor treatment

Authors

Tommy Y. Yu, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, USA.
Zartash Gul, Advocate Health - MidwestFollow
Alicia M. Hunt, Advocate Health - Midwest
Michael J. Williams, Advocate Health - MidwestFollow
Alexander M. Maley, Advocate Health - MidwestFollow

Recommended Citation

Yu TY, Gul Z, Hunt AM, Williams MJ, Maley AM. Development of Subcutaneous Panniculitis-Like T-cell Lymphoma After Immune Checkpoint Inhibitor Treatment. Cureus. 2024;16(8):e66974. Published 2024 Aug 15. doi:10.7759/cureus.66974

Affiliations

Aurora St. Luke's Medical Center

Abstract

Program death 1 (PD-1) inhibitors such as nivolumab are immune checkpoint inhibitors that have revolutionized the treatment of metastatic melanoma. Despite its success in treating melanoma, immune activation can lead to immune-related adverse effects, which are experienced by half of melanoma patients treated with PD-1 inhibitors. Despite the common frequency of immune-mediated adverse events, the development of a secondary lymphoma is exceedingly rare. We present the case of a 53-year-old woman diagnosed with stage IV metastatic melanoma, treated with nivolumab, who subsequently developed fatal subcutaneous panniculitis-like T-cell lymphoma (SPTCL).

Type

Article

PubMed ID

39280467